Insider Buying: STAAR Surgical (NASDAQ:STAA) Major Shareholder Purchases $553,925.40 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 31,780 shares of the company’s stock in a transaction on Wednesday, April 2nd. The shares were purchased at an average price of $17.43 per share, for a total transaction of $553,925.40. Following the purchase, the insider now owns 12,487,044 shares in the company, valued at approximately $217,649,176.92. The trade was a 0.26 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, March 31st, Broadwood Partners, L.P. bought 22,189 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.46 per share, with a total value of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. purchased 3,620 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.48 per share, for a total transaction of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. purchased 249,503 shares of STAAR Surgical stock. The shares were bought at an average cost of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The stock was bought at an average price of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. purchased 36,532 shares of STAAR Surgical stock. The shares were bought at an average price of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. acquired 259,616 shares of STAAR Surgical stock. The stock was bought at an average price of $14.96 per share, for a total transaction of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The stock was purchased at an average price of $21.50 per share, with a total value of $176,751.50.

STAAR Surgical Stock Performance

Shares of STAA opened at $15.92 on Friday. The stock has a 50 day moving average price of $18.82 and a 200 day moving average price of $24.71. STAAR Surgical has a one year low of $13.50 and a one year high of $52.68. The stock has a market capitalization of $785.25 million, a price-to-earnings ratio of -38.83 and a beta of 0.75.

Institutional Investors Weigh In On STAAR Surgical

A number of large investors have recently modified their holdings of the business. Quarry LP purchased a new position in shares of STAAR Surgical in the third quarter worth about $50,000. KLP Kapitalforvaltning AS acquired a new stake in STAAR Surgical in the 4th quarter valued at about $180,000. Bridgefront Capital LLC lifted its stake in STAAR Surgical by 27.2% in the 4th quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock worth $262,000 after purchasing an additional 2,306 shares in the last quarter. FMR LLC boosted its holdings in shares of STAAR Surgical by 79.3% during the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier’s stock worth $263,000 after purchasing an additional 3,136 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of STAAR Surgical in the fourth quarter valued at approximately $278,000. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on STAA shares. Mizuho cut shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $45.00 to $17.00 in a report on Wednesday, February 12th. William Blair cut STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Piper Sandler lowered their price target on STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 12th. Stephens restated an “equal weight” rating and issued a $17.00 price objective on shares of STAAR Surgical in a research report on Tuesday, March 18th. Finally, BTIG Research lowered STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, STAAR Surgical currently has a consensus rating of “Hold” and a consensus price target of $25.29.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.